Mylan Pharmaceuticals received final approval from the FDA for its Abbreviated New Drug Application for Doxycycline Tablets, 150 mg. Doxycycline Tablets are the generic version of Par Pharmaceutical’s Doxycycline Tablets, 150 mg, marketed as Adoxa Tablets by Doak Dermatologics. Doxycycline Tablets had US sales of approximately $34 million for the 12 months ending March 31, 2007 for the 150 mg. strength. In addition to this new product strength, Mylan previously received approval and is marketing the 50 mg, 75 mg and 100 mg strengths of Doxycycline Tablets.
King Pharmaceuticals announced plans to discontinue Florinef (fludrocortisone acetate tablets, USP), a drug used as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison’s disease for the treatment of salt losing adrenogenital syndrome.
